The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face competition from cheaper generics.

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price gain of more than 20%, while most of the group has been flat or down. Financial results the company reported early Thursday seem to validate that recent performance,

Shares of Bristol Myers Squibb Co. BMY shed 3.84% to $57.42 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to 6,083.57 and the Dow Jones Industrial Average DJIA falling 0.28% to 44,747.63.

Bristol-Myers Squibb (SMY) stock falls as its Q4 2024 results beat Street forecasts, but its 2025 outlook fell short of consensus. Read more here.

Bristol Myers Squibb reported stronger-than-expected earnings for the fourth quarter and full year of 2024, but rising generic competition and acquisition-related costs cloud the picture.

The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price gain of more than 20%, while most of the group has been flat or down.